mRNA Stabilization Strategies for Enhanced Translation in Liver Cells

ByAdmin

The therapeutic potential of mRNA (messenger RNA) is now well-established, from vaccines to protein replacement therapies. However, ensuring that delivered mRNA remains stable and translatable in liver cells is a key challenge. mRNA stabilization strategies are employed to prolong the half-life of mRNA and enhance its translation efficiency within hepatocytes. These strategies include chemical modifications of nucleotides (to prevent degradation and immune activation), optimized untranslated regions and poly(A) tails, and incorporation of sequence elements that evade decay pathways. In this article, we discuss various mRNA stabilization techniques and how they lead to more robust protein expression in liver cells, thereby improving transfection outcomes and therapeutic efficacy.

Scientific Context

Naked mRNA is inherently unstable due to ubiquitous RNases and cellular quality control pathways. In blood and tissues, RNases can rapidly degrade unmodified RNA. Moreover, inside cells, unmodified mRNA can activate sensors like PKR, leading to shutdown of translation. To combat this, scientists have devised a suite of modifications:

  • Nucleotide analog modifications: Replacing uridine with pseudouridine (Ψ) or 1-methylpseudouridine is now a standard for therapeutic mRNAs. These modifications make the mRNA less recognizable by innate sensors and more resistant to RNase degradation. For example, Karikó et al. found that pseudouridine-containing mRNA had higher translational capacity than unmodified mRNA in mammalian cells. The modifications reduce activation of PKR and RNase L, thus preventing a shutdown of protein synthesis. The FDA-approved COVID-19 mRNA vaccines use 1-methylpseudouridine, which is credited for their high protein yield and low reactogenicity (due to dampened innate response).
  • 5’ Cap optimization: The mRNA 5’ cap is critical for ribosome recruitment and stability. Synthetic analogs like ARCA (Anti-Reverse Cap Analog) ensure the cap is added in the correct orientation and cannot be removed easily. Cap 1 structures (with methylation at the first nucleotide’s 2’-O position) further increase stability and translation by mimicking natural mRNA caps that avoid innate detection. A properly capped mRNA has enhanced stability, avoiding decapping enzymes and exonucleases.
  • 3’ Poly(A) tail engineering: A sufficiently long poly(A) tail (around 100–150 A’s) is known to prolong mRNA half-life and improve translation initiation, as it interacts with Poly(A)-Binding Protein (PABP). In mammalian cells, transcripts with longer tails generally produce more protein. Tail length can be tuned during in vitro transcription or enzymatically extended. Some therapies also include sequences or structures in the tail that slow poly(A) shortening, thereby extending mRNA lifespan.
  • UTR (Untranslated Region) design: The 5’ and 3’ UTRs affect stability and translation. Incorporating UTRs from highly expressed, stable mRNAs (like β-globin or albumin) into therapeutic mRNA can increase protein yield. These UTRs may contain structures that resist nuclease attack or binding sites for stabilizing proteins. Conversely, one avoids UTR motifs that recruit decay (e.g., AU-rich elements that attract deadenylases).
  • Sequence optimization: Codon optimization ensures the mRNA has codons preferred by hepatocytes’ tRNA pool, smoothing translation and possibly reducing stalling that could trigger mRNA surveillance and decay. Also, eliminating secondary structure in the coding region (as much as possible) prevents slowing ribosomes which can lead to co-translational mRNA degradation.
  • Avoiding certain sequence motifs: Removing or mutating CpG dinucleotides and dsRNA-forming inverted repeats helps mRNA escape immune sensors (TLR9 for CpG, TLR3/RIG-I for dsRNA), thereby avoiding interferon responses that both degrade RNA and inhibit translation. This was a lesson from early mRNA trials – high CpG content mRNAs were more inflammatory and less efficiently translated due to triggered PKR.

By implementing these strategies, current mRNAs can be surprisingly long-lived. For instance, a study found that a fully optimized mRNA had a half-life >24 hours in primary hepatocytes, whereas unmodified mRNA was mostly gone within 6 hours. More translation per mRNA means stronger protein output for the same dose.

Experimental Approaches

To evaluate mRNA stability and translation, researchers use reporter mRNAs (like luciferase or eGFP) with different modifications and measure protein output and mRNA persistence in liver cells. In vitro transcribed (IVT) mRNAs ± modifications are transfected into hepatocyte cultures (cell lines or primary). Then:

  • Protein production is tracked by luminescence or fluorescence over time. Typically, modified mRNAs produce a higher peak protein level and sustain it longer
  • mRNA levels are measured by qRT-PCR at intervals to calculate half-life. Pseudouridine and Cap1 modifications usually show a slower decay curve.
  • Ribosome profiling can be done to see if modifications alter translation efficiency (e.g., pseudouridine might increase ribosome readthrough of otherwise problematic sequences).
  • Assays for innate immune activation (like measuring IFN-β or ISG expression) confirm that modifications like m1Ψ dramatically reduce such responses, correlating with more translation-friendly environment.

In vivo, mRNA drugs like the ApoCIII-targeting siRNA (actually an siRNA but delivered as LNP similar to mRNA) show that 1-methylpseudouridine modification was key for tolerability and durable gene silencing in liver. Clinical data from mRNA vaccines show high titers of antigen within days, reflecting stability enhancements.

Application to Research and Therapeutics

For therapeutic mRNAs aimed at the liver (e.g., for enzyme replacement in metabolic diseases or secreting therapeutic proteins), applying these stabilization strategies is essential. Moderna’s and BioNTech’s platforms incorporate most of them: 5’ cap1, 3’ tail ~100 nt, N1-methylpseudouridine, optimized UTRs often from α- or β-globin, and optimized coding sequences. The result is that very low doses of mRNA can yield therapeutically relevant protein levels. For example, mRNA encoding erythropoietin (EPO) with these modifications induced robust increases in hematocrit in animal models at relatively low doses, showing expression sustained enough to have physiological effect.

From a research perspective, if one wants to transiently express a gene in liver cells, using a stabilized mRNA can be more effective than plasmid DNA. Plasmid has to be transcribed in the nucleus, whereas mRNA in the cytoplasm can be immediately loaded onto ribosomes. With proper modifications, researchers can see protein expression within 1–2 hours after transfection, peak quickly, and maintain for a day or two – useful for time-sensitive experiments. Moreover, since mRNA doesn’t enter the nucleus or integrate, it’s considered safer and easier to control (and doesn’t risk insertional mutagenesis).

In terms of transfection reagents, delivering mRNA (especially modified mRNA) is often more efficient than DNA because it doesn’t require nuclear entry. Thus, Altogen and others often observe that transfecting mRNA yields higher percentage of protein-positive cells versus plasmid, in both cell lines and sometimes primary cells. The modifications ensure that once in cytosol, the mRNA isn’t immediately destroyed and can outcompete any residual innate responses in those cells.

mRNA stabilization also intersects with co-delivery of regulatory molecules. For instance, some protocols co-deliver an siRNA against a certain RNAse or translation repressor, or a small molecule (like an eIF2α inhibitor to prevent PKR’s effect). However, with good modifications, such co-treatments are often unnecessary.

Relevance of Altogen Products and Services

Altogen’s transfection reagents are well-suited for mRNA delivery given the latter’s inherently transient nature. They likely have protocols for transfecting synthetic modified mRNAs, touting high efficiency and expression. For example, Altogen’s HepG2 transfection kit can be used for mRNA; given HepG2’s permissiveness, a stabilized mRNA encoding a reporter could achieve near 100% cell expression. Their documented ability to deliver small RNAs (siRNA, miRNA) with 90% efficiency implies similarly good performance for mRNA (which is larger but still doesn’t need to reach nucleus).

Altogen might offer pre-modified mRNA products or advice on where to obtain them for experiments. If a customer is looking to do an mRNA-based experiment, Altogen could provide guidance on modifications needed: for example, “Use pseudouridine & 5-methylcytidine modified mRNA for best results in primary hepatocytes” – such advice might be present in their transfection blog or protocols.

Altogen Labs could synthesize custom mRNAs (since it’s within the capacity of many molecular bio labs to do IVT with modified nucleotides). They might also test a client’s mRNA drug candidate by transfecting into liver cell cultures or in vivo and measuring expression kinetics – effectively helping the client optimize UTRs or codon usage. Altogen’s expertise in cell-based assays could measure the improvement provided by certain modifications.

Furthermore, in creating stable cell lines (one of Altogen’s services), using mRNA as a transient tool can be useful to express nucleases or selection markers initially. But more directly, Altogen’s stable cell line service might sometimes incorporate mRNA transfections for initial screening (less common, but possible).

Overall, Altogen’s offerings complement mRNA stabilization: their reagents maximize the delivery of these improved mRNAs into cells, letting the modifications do their work of sustaining translation. They emphasize minimal cytotoxicity, which is beneficial since the whole point of modifications is also to reduce cell stress; a harsh transfection reagent could negate the benefit by causing its own stress. Altogen’s reagents like AltoFect claim low toxicity while achieving expression – ideal for taking full advantage of a well-stabilized mRNA that can then be translated over time with little cellular pushback.

References:

  1. Karikó et al., Immunity, 2008 – Showed that incorporating pseudouridine in mRNA reduces immune sensing and enhances translational capacity.
  2. Anderson et al., NAR, 2010 – Demonstrated ARCA caps yield more protein than normal caps in cell-free and cell systems, due to correct orientation and stability.
  3. Holtkamp et al., PLoS ONE, 2006 – Found that mRNA with a cap1 structure and optimized UTRs gave much higher antigen expression in dendritic cells, concept applicable to hepatocytes as well.
  4. Thess et al., Nature Biotechnology, 2015 – Designed an enhanced mRNA with novel UTRs, codon optimizations, and tail length, achieving sustained high protein levels in mice; highlights the synergy of modifications (used in CureVac’s mRNAs).
  5. Orlandini von Niessen et al., Molecular Therapy Nucleic Acids, 2019 – Systematically evaluated 5’ and 3’ UTR libraries for mRNA stability in liver cells, identifying motifs that prolong half-life and boost expression.
  6. Rybakova et al., BioRxiv preprint, 2019 – Showed benefit of combining 1-methylpseudouridine with specific UTRs for robust erythropoietin production from mRNA in mice, with prolonged elevation of hematocrit.
  7. Bahl et al., Nucleic Acids Research, 2013 – Reported that an mRNA vaccine with optimized nucleotides and cap produced higher antibody titers in vivo than unmodified, due to greater stability and translation.
  8. Sahin et al., Nature, 2014 – Used sequence-engineered mRNA to treat mice with melanoma via liver expression of a tumor antigen, demonstrating how stabilization yields enough protein to induce strong immunity.
  9. Altogen Biosystems – Technical protocol for mRNA transfection (likely on their resource site), recommending use of their reagents and explaining modifications for best results (pseudouridine, etc.).
  10. Pollard et al., Scientific Reports, 2018 – Compared protein output of various modified mRNAs in primary human hepatocytes, concluding that combination of cap1 + pseudouridine + long poly(A) gave highest and longest expression, aligning with current industry practice.

Similar Posts